Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma

(MedPage Today) -- CHICAGO -- Oral vorasidenib monotherapy significantly improved progression-free survival (PFS), and delayed the time to next therapy, in patients with mutated, low-grade glioma, according to an interim analysis of the INDIGO...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news